The TBCRC-056 trial showed a 50% pCR rate in TNBC patients with BRCA or PALB2 mutations treated with niraparib and dostarlimab. sTILs increased significantly in both treatment arms, with higher ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback